ProCE Banner Activity

Safety and Clinical Activity of Mutant IDH1 Inhibitor AG-120 in Pretreated IDH1-Mutant Cholangiocarcinoma

Slideset Download
Conference Coverage
AG-120 was associated with fatigue and gastrointestinal toxicities and prolonged stable disease.

Released: June 06, 2017

Expiration: June 05, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology